more

Mersana Therapeutics (MRSN)

(Delayed Data from NSDQ)

$3.17 USD

+0.01 (0.32%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $3.18 +0.01 (0.32%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on May 09,2022

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -90.32% and 89.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MRSNPositive Net Change

Certara, Inc. (CERT) Matches Q1 Earnings Estimates

by Zacks Equity Research Published on May 05,2022

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Sangamo (SGMO): Can Its 9.6% Jump Turn into More Strength?

by Zacks Equity Research Published on March 30,2022

Sangamo (SGMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on February 28,2022

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1.49% and 10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on February 24,2022

Cytokinetics (CYTK) delivered earnings and revenue surprises of 59.55% and 931.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?

by Zacks Equity Research Published on February 24,2022

Mersana Therapeutics (MRSN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

MRSNPositive Net Change

medical

Analysts Estimate Mersana Therapeutics, Inc. (MRSN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on February 18,2022

Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRSNPositive Net Change

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 09,2021

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -8.62% and 10.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

MRSNPositive Net Change

Earnings Preview: Mersana Therapeutics, Inc. (MRSN) Q3 Earnings Expected to Decline

by Zacks Equity Research Published on November 01,2021

Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRSNPositive Net Change

New Strong Sell Stocks for September 14th

by Zacks Equity Research Published on September 14,2021

ATR, FTAI, HGEN, LMB, and MRSN have been added to the Zacks Rank #5 (Strong Sell) List on September 14, 2021.

New Strong Sell Stocks for May 28th

by Zacks Equity Research Published on May 28,2021

ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on May 10,2021

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -28.21% and -95.60%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

MRSNPositive Net Change

Moving Average Crossover Alert: Mersana Therapeutics (MRSN)

by Zacks Equity Research Published on March 12,2021

Mersana Therapeutics (MRSN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

MRSNPositive Net Change

medical

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on February 26,2021

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -27.27% and -97.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?